Background
Lipopolysaccharides (LPSs) are found in the outer membranes of gram-negative bacteria, such as Salmonella and Escherichia coli. 1 Injection of LPS evokes proinflammatory response, and in the blood may result in fever, shock, organ failure, and death. 2 LPS is used in the modeling of endotoxemia in experimental models. 3 Two cyclooxygenase enzymes are known. Cyclooxygenase-2 (COX-2) regulates release of prostaglandins important for the inflammatory response. 4 Expression of COX-2 is increased after exposure to LPS. 5 Monitoring the serum levels of cytokines such as interlukin-1 (IL-1), interlukin-6 (IL-6), or tumor necrosis factor-α (TNF-α) may be an effective method for the evaluation of inflammatory response and early detection of acute phase reactions. [6] [7] [8] Pro-inflammatory cytokines, such as TNF-α and IL-6 were induced by endotoxins like LPS, leading to inflammation and coagulation cascades. These cytokines may trigger the expression of tissue factors in monocytes and endothelial cells. 9 C-reactive protein (CRP) is produced by the liver in response to inflammation regulated by IL-6, IL-1, and TNF-α. 10 IL-6in LPS challenge and inflammation induces weight loss, hypoglycemia and fibrinogen production.
11
Nonsteroidal anti-inflammatory drugs (NSAIDs) are used as analgesics, anti-inflammatory drugs, and antipyretics. 12 NSAIDs block the action of COX, thereby reducing symptoms of inflammation. 13 Ruetten and Thiemermann in a recent study demonstrated that the expression of COX-2 caused by LPS in the rat was prevented by dexamethasone. 14 Yazar et al showed that flunixin meglumine inhibited the increase of inflammatory cytokine levels (TNFα and IL-1) in LPSinduced endotoxic mice. of indomethacin, naproxen, and several other agents. [16] [17] [18] [19] E. coli LPS is one of the most potent stimuli for cytokine release and is used as an experimental model.
Objective
The objective of the present work was to study the effect of diclofenac on hematological parameters and inflammatory markers during intraperitoneal injection of E. coli LPS in rats.
Materials and Methods

Animal and Experimental Design
Ninety-six male Wistar rats were used in this study. The rats were divided randomly into 8 equal groups. Groups I, II, and III were injected intraperitoneally with 100, 200 and 300 μg/kg LPS from E. coli (Serotype 0111:B4; Sigma-Aldrich, USA). Groups IV, V, and VI were injected with LPS at a dose similar to the above groups, plus diclofenac (75 mg, Caspian Co., Iran) at a dose of 2.5 mg/kg, intramuscularly (IM). Group VII received only diclofenac at the same dose. Group VIII (control group) received normal saline. Blood samples were collected from the heart at 0, 1, 6 and 24 hours and collected into 3.8% sodium citrate tubes (Sigma-Aldrich, USA). Blood samples were collected to assay the hematological and inflammatory parameters. The sera were separated and stored at -20 o C.
Analysis of Hematological Parameters and Inflammatory Markers
Blood smears were prepared for total and differential leukocyte count. White blood cells were counted by Neubar haemocytometer. Differential leukocyte count was performed with blood smears stained with Giemsa (Labtron Co., UK). CRP and fibrinogen levels were measured by kits (Mahsayaran Co., Iran), (Parsazmoon Co., Iran) using Clauss assay and an Immunoturbidimetry assay, respectively.
Statistical Analysis
Statistical analysis was performed using SPSS version 16.0. Duncan's post hoc test was used for comparison of groups and analyses of variance. P < 0.05 was considered statistically significant.
Results
The results showed that LPS reduced WBC count at 1 and 6 hours after injection of LPS compared with control group, mainly due to a decrease in neutrophil and lymphocyte counts (Tables 1 and 2) (P < 0.05). In LPS group, the total leukocyte count, neutrophils and lymphocytes increased at 24 hours (P < 0.05) ( Tables 1 and 2 ). Pretreatment with diclofenac did not change hematological parameters. CRP was significantly increased in LPS group after 6 and 24 hours (P < 0.05). The levels of CRP in diclofenac-treated groups were decreased (P < 0.05) ( Table 3) . Fibrinogen was relatively increased in LPS group. It was not decreased in the treated groups Compared with LPS group (P < 0.05) ( Table 4) .
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Gram-negative bacteria that can cause inflammation, septic shock, and death. 20 NSAIDs are used for treating inflammatory diseases. 21, 22 The results of this study showed that intraperitoneal injection of LPS could cause alteration in hematological parameters, as the level of WBC in LPS group significantly reduced, and pretreatment with diclofenac could not restore these parameters to normal levels ( Table 1 ). The post-endotoxin leukopenia mainly resulted from a decrease in circulating neutrophil count. 23, 24 Neutrophilia and Lymphopenia were observed in response to the injection of LPS. This, consequently, caused an increase in the leukocyte counts, and leukocytosis, which was in accordance with previous findings. 25, 26 Pretreatment with diclofenac could not inhibit the leukocyte changes (total and diff. count). Previous reports have demonstrated that leukopenia and neutropenia in response to injection of LPS is induced by cytokines which causes margination of neutrophils followed by leukocytosis. 27 Neutrophil migration was inhibited, since LPS affected neutrophil chemotaxis. Intraperitoneal injection of LPS alone, in some studies, showed a significant dose-and time-dependent neutrophil migration for mice and horses. 25, 28 Inflammatory cytokines play an important role in inflammatory response. 29 Interleukins, including IL-1, IL-6, and IL-8 have strong influences on inflammatory responses. [30] [31] [32] CRP and fibrinogen are produced in response to inflammation regulated by IL-1, IL-6, and TNF-α. 10, 11 Our results showed that intraperitoneal injection of LPS could elevate the production of CRP. Pretreatment with diclofenac (at a dose of 2.5 mg/ kg) could reduce the production of CRP (Table 3) . Moreover, the content of fibrinogen was significantly increased after injection of LPS, and pretreatment with diclofenac (at a dose of 2.5 mg/kg) could not decrease the level of fibrinogen (Table 4) . Teeling et al reported that pretreatment with indomethacin and ibuprofen did not reduce the effect of LPS in changing peripheral IL-6, IL-1β, and TNF-α levels; but dexamethasone altered cytokine production in mice. 33 
Conclusion
It can be concluded that diclofenac had different effects on LPS-treated rats. Our results demonstrated that pretreatment with diclofenac could significantly reduce the changes of serum CRP level. The range of these changes should be considered in the evaluation of bacterial toxemia status, and effects of NSAIDs in rats. 
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